Background The immunosuppressive tumor microenvironment (TME) of colorectal cancer
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …

Cancer immunotherapy, including immune checkpoint blockade and CAR-T cell therapy,
has introduced revolutionary approaches to treating patients with cancer. The success and …

Blockade of inhibitory immune checkpoints (ICs) is a promising therapeutic approach;
however, it has shown limited success in some cancers including colorectal cancer (CRC) …

Male sex is a risk factor for colorectal cancer (CRC) with higher illness burden and earlier
onset. Thus, we hypothesized that loss of chromosome Y (LOY) in the tumor micro …

Despite recent advances in colorectal cancer (CRC) treatment, a large proportion of patients
show limited responses to therapies, especially in advanced stages. There is an urgent …

Receptor-interacting protein kinase 3 (RIPK3) is essential for mucosal repair in inflammatory
bowel diseases (IBD) and colorectal cancer. However, its role in tumor immunity is unknown …

Microsatellite stable colorectal cancers (MSS-CRC) are resistant to anti-PD-1/PD-L1 therapy
but the combination of immune checkpoints inhibitors (ICI) could be a clue to reverse …

High CD8+ T cell infiltration in colorectal cancer (CRC) should suggest a favorable
prognosis and a satisfactory response to immunotherapy; however, the vast majority of …

Simple Summary TGFβ and TIM-3 have been implicated in driving immune evasion and
poor response to anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs). Using large-scale …

Adoptive cell therapy with the use of tumor-infiltrating lymphocytes (TILs) is a very promising
immunotherapeutic approach for the treatment of patients with colorectal cancer (CRC) …